RxDoctor Payments Data

John D Andrea, MD

Family Medicine · East Rutherford, NJNPI 1801213228

Payments from drug & device makers

$1,002in general payments, 2019–2025

Across 72 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$237
  • GSK$153
  • Incyte Corporation$121
  • Lilly USA, LLC$105
  • Exact Sciences$91
  • Abbott$67
  • plus $229 from 10 others

What the payments were for

  • Food & beverage$83784%
  • Education$16516%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,002 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$290,698
Medicare patients
439
Services billed
8,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$32,715
EliquisApixaban18$27,464
JardianceEmpagliflozin13$22,359
JanuviaSitagliptin Phosphate13$19,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,764
MounjaroTirzepatide11$11,365
DexilantDexlansoprazole20$7,325
RestasisCyclosporine12$6,752
Atorvastatin Calcium394$3,836
Advair DiskusFluticasone Propion/Salmeterol13$2,560
Rosuvastatin Calcium161$2,450
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,336
SynthroidLevothyroxine Sodium28$2,307
Ezetimibe27$2,253
Losartan Potassium211$2,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62$32,71534 claims
PfizerEliquis$15$27,46418 claims
MerckJanuvia$29$19,29713 claims
GSKTrelegy Ellipta$153$15,76419 claims
Lilly USA, LLCMounjaro$105$11,36511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in East Rutherford

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →